Abstracts tagged "autoimmune diseases"

Abstract Number: 0069 • ACR Convergence 2023
All-trans Retinoic Acid (atRA) Enhances FoxP3 Protein Stability Under Inflammatory Conditions Through Altering the FoxP3 Protein-interactome
William Willis¹, shane Bruckner² and wael Jarjour², ¹Ohio State University, Reynoldsburg, OH, ²Ohio State University, Columbus, OH
Background/Purpose: Treg cells play a central role in the tolerance of self-antigens and prevention of autoimmune disease. FoxP3 is a Treg-specific transcription factor that plays…
Abstract Number: 0137 • ACR Convergence 2023
Incidence of and Risk Factors for Myelodysplastic Syndromes in Patients with Rheumatologic Diseases
YoungEun Kim¹, Hansun Song¹, Wook Jang Seo², Jinseok Kim³, Soo Min Ahn¹, Seokchan Hong⁴, Ji-Seon Oh⁵, Chang-Keun Lee⁶, Bin Yoo⁶ and Yong-Gil Kim¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ²Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea, ³Department of Rheumatology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju-si, Jeju-do, South Korea, La Jolla, CA, South Korea, ⁴Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ⁵Department of Information Medicine, Big Data Research Center, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea, ⁶Asan Medical Center, Seoul, South Korea
Background/Purpose: Myelodysplastic syndrome (MDS) is a hematologic disorder characterized by dysplasia of bone marrow, leading to ineffective hematopoiesis and cytopenia. Despite sporadic reports of associations…
Abstract Number: 0266 • ACR Convergence 2023
E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez², Fernanda Genre Romero², Belén Atienza-Mateo³, Victor Mora-Cuesta⁴, David Iturbe-Fernández⁴, Leticia Lera-Gómez⁵, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Ricardo Blanco¹, Jose Cifrian⁶, Miguel A Gonzalez-Gay⁷ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the most critical comorbidities in autoimmune diseases (AD), particularly in rheumatoid arthritis (RA) and systemic sclerosis (SSc)…
Abstract Number: 0472 • ACR Convergence 2023
Contraception Choices in Individuals with Inflammatory Arthritis and Lupus-like Disease Differ Based on Diagnosis and Teratogen Use
Caroline Siegel¹, Medha Barbhaiya², Lucy Masto¹, Amaya Smole¹, Bessie Stamm¹, Jonah Levine¹, Sarah Lieber², Lisa Mandl², Michael Lockshin² and Lisa Sammaritano², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Individuals with systemic rheumatic disease (SRD) underutilize effective contraception even when prescribed teratogenic medications. As disease-related factors may impact contraception choice, we evaluated the…
Abstract Number: 0675 • ACR Convergence 2023
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
allyson egan¹, Pasupathy Sivasothy² and David Jayne³, ¹Trinity Health Kidney Centre, Tallaght University Hospital, Ireland, Dublin, Ireland, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0934 • ACR Convergence 2023
Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis
Hiroshi Matsuura¹, Masahiro Kondo¹, Ryoko Ohno¹, Akina Ishii¹, Mariam Piruzyan¹, Kaori Funayama¹, Yuuichi Ono¹, Atsushi Iwamura¹, Tadashi Endo¹, Tomoya Akashi¹, Taizo Tomari², Noriko Uchiyama², Noriyasu Seki¹, Kenji Chiba¹, Gabriela Kania³, Przemyslaw Blyszczuk⁴, Oliver Distler⁵, Tsutomu Takeuchi⁶ and Yuko Kaneko⁷, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Japan, ³University of Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Targeted small-molecule therapies to autotaxin (ATX), the lysophosphatidic acid (LPA)-producing enzyme, have been shown to be potentially effective in systemic sclerosis (SSc), but the…
Abstract Number: 1068 • ACR Convergence 2023
Multidisciplinary Prospective Study of Patients Treated with Immune Checkpoint Inhibitors Who Developed Rheumatic Immune-related Adverse Events
Mª Carmen López-González¹, Natividad Martínez Banaclocha², Montserrat García Araque², Yoel Montoyo Pujol² and Mariano Andrés³, ¹General University Hospital Dr. Balmis, Alacante, Spain, ²General University Hospital Dr. Balmis, Alicante, Spain, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain
Background/Purpose: Immune checkpoint inhibitors (ICIs), by activating the immune system (specifically, T-cells), foster the reaction against tumor cells. However, parallelly, autoimmune phenomena, known as immune-…
Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Hermine Brunner¹, Diego Oscar Viola², Richard Dimelow³, Inmaculada Calvo Penadés⁴, Christel Wilkinson⁵, Juan Cruz Rizo Rodriguez⁶, Alina Boteanu⁷, Sylvia Kamphuis⁸, Kirsten Minden⁹, Gerd Horneff¹⁰, Jordi Anton¹¹, Masaaki Mori¹², Yuichi Yamasaki¹³, Jose Miyar Olaiz¹⁴, Rebecca Marino¹⁵, Andre van Maurik¹⁶, Mohamed Okily¹⁷, Emad Yanni¹⁸ and Paul WIlde¹⁹, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²CAICI Institute, Pediatric Rheumatology, Santa Fe, Argentina, ³GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, Stevenage, United Kingdom, ⁴Hospital Universitario y Politécnico La Fe, Pediatric Rheumatology Unit, València, Spain, ⁵GlaxoSmithKline, Clinical Statistics, Stevenage, United Kingdom, ⁶Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, San Luis Potosí, Mexico, ⁷Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ⁸Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁹Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany, ¹⁰Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Tokyo Medical and Dental University Hospital, Department of Lifetime Clinical Immunology, Tokyo, Japan, ¹³Kagoshima University Hospital, Department of Pediatrics, Kagoshima, Japan, ¹⁴GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ¹⁵GlaxoSmithKline, Safety Evaluation and Risk Management, Durham, NC, ¹⁶GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Clinical Development, ImmunoInflammation, Brentford, United Kingdom, ¹⁸GlaxoSmithKline, Clinical Development, Rockville, MD, ¹⁹GlaxoSmithKline, Clinical Development, Brentford, United Kingdom
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…
Abstract Number: 1514 • ACR Convergence 2023
Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders
Andy Abril¹, Isabel Mira-Avendano², Nisha Durand¹, Hassan Baig¹, augustine Lee¹, Meghan Baer¹ and Abba Zubair¹, ¹Mayo Clinic, Jacksonville, FL, ²University of Texas, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in connective tissue disorders (CTD) including rheumatoid arthritis, scleroderma and inflammatory myopathies.…
Abstract Number: 1708 • ACR Convergence 2023
In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity
Yan Du¹, Evan Hsu², Kailey Brodeur³, Meng Liu⁴, Mindy Lo⁵, Craig Platt³ and Pui Lee⁵, ¹Harvard medical school, Boston, MA, ²Wesleyan University, Newton, MA, ³Boston Children's Hospital, Boston, MA, ⁴Southern Medical University, Boston, MA, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Systemic autoimmunity can be driven by monogenic or polygenic risk variants. We aimed to characterize the genetic basis of disease in a family with…
Abstract Number: 1895 • ACR Convergence 2023
Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies
Pritee Shrestha¹, Peter Larsen¹ and Pablo Weilg Espejo², ¹Mercy One North Iowa Medical Center, Mason City, IA, ²Boston Medical Center, Chelsea, MA
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of cardiovascular disease (CVD). Despite multiple CVD risk tools available, reliability to RA population is…
Abstract Number: 2036 • ACR Convergence 2023
Switch or Stay the Same? Preferences of People with Autoimmune Disease on Rituximab for Different Types of COVID-19 Vaccine Boosters
Todd Wilson¹, Paul R. Fortin², Ines Colmegna³, Sonia Theriault⁴, Nathalie Amiable⁵, Alexandra Godbout⁵ and Glen Hazlewood¹, ¹University of Calgary, Calgary, AB, Canada, ²Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Centre ARThrite - CHU de Quebec - Universite Laval, Quebec City, QC, Canada
Background/Purpose: COVID-19 vaccines are now being offered as regular boosters every 6-12 months for people with autoimmune rheumatic diseases, particularly for people on rituximab, where…
Abstract Number: 2331 • ACR Convergence 2023
Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus
Kevin Thomas¹, Miles Smith¹, Carla Guthridge¹, Nicolas Dominguez¹, Susan Macwana¹, Wade DeJager¹, Catriona Wagner¹, Peter Schafer², Stan Kamp¹, Betty Diamond³, David Wofsy⁴, Aikaterini Thanou⁵, Cristina Arriens⁶, Cynthia Aranow³, Joan Merrill¹, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Bristol Myers Squibb, Belle Mead, NJ, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴University of California San Francisco, San Francisco, CA, ⁵University of Oklahoma Health, Edmond, OK, ⁶Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK
Background/Purpose: Abatacept (ABA) is a fusion protein that disrupts T cell co-stimulation by inhibiting interactions between CD28 and CD80/86. ABA is effective in RA, but…
Abstract Number: 2519 • ACR Convergence 2023
A Phase II Clinical Study to Investigate the Efficacy and Safety of Hemay005 Tablets in Patients with Active Behçet`sDisease
Charles Jones¹, Zhanguo Li², Zhuoli Zhang³, Jian Wu⁴, Guixiu Shi⁵, Wenjie Zheng⁶, Jianping Tang⁷, Xiaobing Wang⁸, Lie Dai⁹, Lin Chen¹⁰, Yasong Li¹¹, Ling Wu¹², Yongfu Wang¹³, Shengyun Liu¹⁴, Yao Ke¹⁵, Jin Lin¹⁶, Zhenchun Zhang¹⁷, Jiankang Hu¹⁸, Wantai Dang¹⁹, Songlou Yin²⁰, Xin Tang²¹, Mingfei Zhu²², Jinfeng Lin²², Richard Jones²², Weiguo Wan²³ and xianjun Hu²², ¹Hemay Pharmaceuticals, Tianjin, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ³Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ⁴Suzhou University Affiliated First Hospital, Suzhou, China, ⁵the First Affiliated Hospital of Xiamen University, Xiamen, China, ⁶Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ⁷Shanghai Tongji Hospital, Shanghai, China, ⁸The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁹Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ¹⁰Jilin Provincial People's Hospital, Changchun, China, ¹¹11Zhejiang Provincial People's Hospital, Hangzhou, China, ¹²University of Hong Kong Shenzhen Hospital, Shenzhen, China, ¹³The First Affiliated Hospital of Baotou Medical College, Baotou, China, ¹⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ¹⁵Jiangsu Provincial People's Hospital, Nanjing, China, ¹⁶The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹⁷Linyi People's Hospital, Linyi, China, ¹⁸Pingxiang People’s Hospital, PingXiang, China, ¹⁹The First Affiliated Hospital of Chengdu Medical College, Chengdu, China, ²⁰Xuzhou Medical University Affiliated Hospital, Xuzhou, China, ²¹Bestudy (Shanghai) Medical Technology Co., Ltd, Shanghai, China, ²²Clinical Department, Tianjin Hemay Pharmaceutical Co., Ltd., Tianjin, China, ²³Huashan Hospital Affiliated to Fudan University, Shanghai, China
Background/Purpose: Behçet's disease (BD) is a chronic and recurrent vascular inflammatory disease with major manifestations including oral ulcers, genital ulcers, skin damage and ophthalmitis, and…
Abstract Number: 0071 • ACR Convergence 2023
Sex Based Differences in Morphological and Functional Niches of the Human Thymus, Identified by Non-supervised Spatial Transcriptomic Profiling, May Underlie Sex Bias in Autoimmune Disease
Viktoria Hennings, Anneke van Dijk, Andri Lemarquis, Christina Lundqvist and Olov Ekwall, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Females exhibit a more robust response to both self- and non-self-antigens than males which manifests as higher prevalence of autoimmune disease, eg. rheumatic diseases,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].